BVXV BiondVax Pharmaceuticals Ltd.

5.95
+0.01  (0%)
Previous Close 5.94
Open 5.96
Price To book 6.54
Market Cap 38886160
Shares 6,535,489
Volume 1,416
Short Ratio 0.12
Av. Daily Volume 33,080

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b data released July 20, 2017 - endpoints met.
M-001
Universal flu vaccine

Latest News

  1. BiondVax and NIH Sign Clinical Trial Agreement for a Phase 2 Trial in the U.S. with BiondVax's Universal Flu Vaccine
  2. BVXV: Raises $10 Million to Help Support M-001 Pivotal P3 Program as Standalone Universal Influenza Vaccine
  3. BiondVax Announces Closing of $10 Million Public Offering of American Depositary Shares and Exercise of Over-allotment Option
  4. BiondVax Announces Pricing of Public Offering of American Depositary Shares
  5. BiondVax Announces Public Offering of American Depositary Shares
  6. Should You Buy BiondVax Pharmaceuticals Ltd (BVXV)?
  7. Featured Company News - Oncobiologics Announces Partnership with GMS Tenshi Holdings; Set to Accelerate the Commercialization of Biosimilar Candidates
  8. Dual-Listed BiondVax to Voluntarily Delist from Tel Aviv Stock Exchange
  9. BiondVax Provides Second Quarter 2017 Financial Results and Update
  10. BiondVax Receives Additional Grant Funding
  11. BVXV: Positive Results From Phase 2b Trial of M-001; Ready to Move Into Pivotal P3 Trial as Standalone Universal Influenza Vaccine
  12. BiondVax Reports Positive Phase 2b Clinical Trial Results for its Universal Flu Vaccine
  13. BiondVax Signs Lease Agreement for Mid-Size Commercial Facility to Manufacture Universal Flu Vaccine
  14. BVXV: Secures $22 Million Loan Agreement with European Investment Bank…
  15. BiondVax's CEO Provides First Half 2017 General Corporate Update
  16. European Investment Bank (EIB) Supports Late-Stage Development and Production of BiondVax's Universal Flu Vaccine Candidate Under Horizon 2020 Initiative
  17. Corporate News Blog - Lexicon Pharma's Diabetes Drug Sotagliflozin Shows Positive Top-line Results During Phase-3 Intandem3 Clinical Trials
  18. BVXV: Immunogenicity Results From Phase 2b Trial of M-001 Expected Soon…
  19. BiondVax Announces First Quarter 2017 Financial Results and Update
  20. BVXV: Awarded Grant to Build Commercial Scale Facility for Production of M-001